107 related articles for article (PubMed ID: 29950811)
1. Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer.
De Luca R; Blasi L; Alù M; Gristina V; Cicero G
Drug Des Devel Ther; 2018; 12():1769-1775. PubMed ID: 29950811
[TBL] [Abstract][Full Text] [Related]
2. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
[TBL] [Abstract][Full Text] [Related]
5. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
Borazanci E; Von Hoff DD
Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):739-47. PubMed ID: 24882381
[TBL] [Abstract][Full Text] [Related]
6. Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer.
Hoy SM
Drugs; 2014 Oct; 74(15):1757-68. PubMed ID: 25260887
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice.
Casanova-Martinez C; Romero-Ventosa EY; González-Costas S; Arroyo-Conde C; Piñeiro-Corrales G
J Cancer Res Ther; 2018 Sep; 14(Supplement):S730-S735. PubMed ID: 30249895
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.
Huang Y; Liang W; Yang Y; Zhao L; Zhao H; Wu X; Zhao Y; Zhang Y; Zhang L
BMC Cancer; 2016 Jul; 16():464. PubMed ID: 27411683
[TBL] [Abstract][Full Text] [Related]
9. Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
Xie Y; Gong C; Zhang J; Wang L; Cao J; Tao Z; Li T; Zhao Y; Li Y; Hu S; Wang B; Hu X
BMC Cancer; 2021 Nov; 21(1):1174. PubMed ID: 34727875
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
11. Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma.
Tian Z; Zhang F; Li P; Wang J; Yang J; Zhang P; Yao W; Wang X
BMC Cancer; 2020 Jul; 20(1):698. PubMed ID: 32723378
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
[TBL] [Abstract][Full Text] [Related]
13. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
14. FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
Safran H; Charpentier KP; Perez K; Mantripragada K; Miner T; DiPetrillo T; Kuritzky B; Apor E; Bishop K; Luppe D; Mitchell K; Rosati K
Am J Clin Oncol; 2016 Dec; 39(6):619-622. PubMed ID: 26523444
[TBL] [Abstract][Full Text] [Related]
15. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma.
Neuzillet C; Babai S; Kempf E; Pujol G; Rousseau B; Le-Louët H; Christophe Tournigand
Medicine (Baltimore); 2016 Jun; 95(26):e4006. PubMed ID: 27368013
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma.
Miyashita T; Tajima H; Makino I; Okazaki M; Yamaguchi T; Ohbatake Y; Nakanuma S; Hayashi H; Takamura H; Ninomiya I; Fushida S; Kishimoto K; Harmon JW; Ohta T
Anticancer Res; 2018 Jan; 38(1):337-343. PubMed ID: 29277792
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
[TBL] [Abstract][Full Text] [Related]
18. Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life.
De Luca R; Profita G; Cicero G
Onco Targets Ther; 2019; 12():1621-1627. PubMed ID: 30881017
[TBL] [Abstract][Full Text] [Related]
19. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer.
Neesse A; Michl P; Tuveson DA; Ellenrieder V
Z Gastroenterol; 2014 Apr; 52(4):360-6. PubMed ID: 24687799
[TBL] [Abstract][Full Text] [Related]
20. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
